Department of Population Health, NYU School of Medicine, New York, New York; Department of Medicine, NYU School of Medicine, New York, New York.
Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
J Am Coll Cardiol. 2014 Jan 21;63(2):123-30. doi: 10.1016/j.jacc.2013.08.1628. Epub 2013 Sep 25.
The study sought to assess the quality of care for heart failure patients who are hospitalized for all causes.
Performance measures for heart failure target patients with a principal diagnosis of heart failure. However, patients with heart failure are commonly hospitalized for other causes and may benefit from treatments such as angiotensin-converting enzyme (ACE) inhibitors for left ventricular (LV) systolic dysfunction.
We assessed rates of compliance with care measures for patients hospitalized with acute or chronic heart failure in the ARIC (Atherosclerosis Risk In Communities) study surveillance catchment area from 2005 to 2009. Rates of compliance were compared between patients with a principal discharge diagnosis of heart failure and those with another principal discharge diagnosis.
Of 4,345 hospitalizations of heart failure patients, 39.6% carried a principal diagnosis of heart failure. Patients with a principal heart failure diagnosis had higher rates of LV function assessment (89.1% vs. 82.5%; adjusted prevalence ratio [aPR]: 1.07; 95% confidence interval [CI]: 1.04 to 1.10) and discharge ACE inhibitor/angiotensin receptor blocker (ARB) in LV dysfunction (64.1% vs. 56.3%; aPR: 1.11; 95% CI: 1.03 to 1.20) as compared to patients hospitalized for another cause. LV assessment and ACE inhibitor/ARB use were associated with reductions in 1-year post-discharge mortality (adjusted odds ratio: 0.66, 95% CI: 0.51 to 0.85; adjusted odds ratio: 0.72, 95% CI: 0.54 to 0.96, respectively) that did not differ for patients with versus without a principal heart failure diagnosis.
Compared with individuals hospitalized with a principal diagnosis of heart failure, heart failure patients hospitalized for other causes were less likely to receive guideline recommended care. Quality initiatives may improve care by targeting hospitalizations with either principal or secondary heart failure diagnoses.
本研究旨在评估因各种原因住院的心力衰竭患者的护理质量。
心力衰竭的绩效指标针对的是主要诊断为心力衰竭的患者。然而,患有心力衰竭的患者通常因其他原因住院,并且可能受益于治疗,如血管紧张素转换酶(ACE)抑制剂治疗左心室(LV)收缩功能障碍。
我们评估了 2005 年至 2009 年 ARIC(社区动脉粥样硬化风险)研究监测范围内因急性或慢性心力衰竭住院的患者的护理措施符合率。比较了主要诊断为心力衰竭和其他主要诊断的患者之间的符合率。
在 4345 例心力衰竭患者的住院中,39.6%的患者有主要的心力衰竭诊断。主要心力衰竭诊断的患者 LV 功能评估率较高(89.1% vs. 82.5%;调整后患病率比[aPR]:1.07;95%置信区间[CI]:1.04 至 1.10),左心室功能障碍出院时 ACE 抑制剂/血管紧张素受体阻滞剂(ARB)的使用率较高(64.1% vs. 56.3%;aPR:1.11;95%CI:1.03 至 1.20)与因其他原因住院的患者相比。LV 评估和 ACE 抑制剂/ARB 的使用与 1 年后出院死亡率降低相关(调整后比值比:0.66,95%CI:0.51 至 0.85;调整后比值比:0.72,95%CI:0.54 至 0.96),主要心力衰竭诊断与无主要心力衰竭诊断的患者之间无差异。
与因主要心力衰竭诊断而住院的患者相比,因其他原因住院的心力衰竭患者接受指南推荐的治疗的可能性较小。质量改进措施可以通过针对主要或次要心力衰竭诊断的住院治疗来改善护理。